Direct oral anticoagulants in cancer-associated thrombosis: redefining extended therapy
NCODA Oncology and Hematology Meeting Abstracts · 07.04.2026
DOI: 10.67209/octx2598 ↗Kurz gefasst
Fachartikel in der Zeitschrift NCODA Oncology and Hematology Meeting Abstracts, online erschienen am 07.04.2026. Verfasst von Ofek Raviv. Die Arbeit nennt 11 Literaturangaben.
Abstract (Originalsprache)
Background: Venous thromboembolism (VTE) is a leading cause of morbidity and mortality in cancer, accounting for 15–25% of all VTE cases. Cancer patients have a 4- to 7-fold higher risk of VTE than the general population. Historically, low-molecular-weight heparin (LMWH) was the standard for prophylaxis and treatment. Since 2018, randomized trials and meta-analyses evaluated direct oral anticoagulants (DOACs), leading to updated recommendations from the National Comprehensive Cancer Network and the American Society of Hematology for their use in cancer-associated VTE.
Zitieren
APA
Raviv, O. (2026). Direct oral anticoagulants in cancer-associated thrombosis: redefining extended therapy. NCODA Oncology and Hematology Meeting Abstracts. https://doi.org/10.67209/octx2598
Vancouver
Raviv O. Direct oral anticoagulants in cancer-associated thrombosis: redefining extended therapy. NCODA Oncology and Hematology Meeting Abstracts. 2026. doi:10.67209/octx2598
BibTeX
@article{Raviv2026,
author = {Raviv, Ofek},
title = {Direct oral anticoagulants in cancer-associated thrombosis: redefining extended therapy},
journal = {NCODA Oncology and Hematology Meeting Abstracts},
year = {2026},
doi = {10.67209/octx2598}
}
EUVIMED